Seliciclib alleviates ulcerative colitis by inhibiting ferroptosis and improving intestinal inflammation
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Seliciclib partially inhibits ferroptosis, a form of cell death linked to ulcerative colitis (UC). This finding suggests targeting ferroptosis may offer a new therapeutic strategy for managing UC inflammation.
Area Of Science
- Gastroenterology
- Immunology
- Cell Biology
Background
- Ulcerative colitis (UC) is a chronic inflammatory disease with unclear pathogenesis.
- Ferroptosis, iron-dependent cell death involving reactive oxygen species (ROS), is implicated in disease development.
- The mechanism of seliciclib, an immune inflammation drug, in colitis remains largely unknown.
Purpose Of The Study
- To investigate the role of seliciclib in regulating ferroptosis in ulcerative colitis.
- To explore the potential therapeutic effects of seliciclib on experimental colitis.
- To elucidate the molecular mechanisms underlying seliciclib's action in UC.
Main Methods
- Established a mouse model of UC using dextran sodium sulfate (DSS) and treated with seliciclib.
- Utilized an in vitro model with lipopolysaccharide (LPS) induction and seliciclib treatment.
- Assessed histopathology, inflammatory markers, oxidative stress, and ferroptosis regulators.
Main Results
- Seliciclib administration alleviated symptoms and inflammation in DSS-induced UC mice.
- The drug partially mitigated ferroptosis in both in vivo and in vitro models.
- Bioinformatics analysis suggested Dual oxidase 2 (DUOX2) may be involved in UC ferroptosis, potentially modulated by seliciclib.
Conclusions
- Ferroptosis is significantly associated with colitis development.
- Seliciclib demonstrates a crucial role in modulating ferroptosis and inflammation in UC.
- Inhibiting ferroptosis in the intestinal epithelium presents a promising therapeutic avenue for UC.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...